RBC Capital Rates Hinge Health (HNGE) buy, $75 Price Target

RBC Capital maintains its buy rating for Hinge Health, targeting $75 based on strong business fundamentals, a 9.73% upside from the current price.

By TradeTexts Research Desk · Published Jun 12, 2026, 9:12 PM EDT · Updated Jun 17, 2026, 9:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

RBC Capital rated Hinge Health, Inc. ($HNGE) "buy" with a $75 price target on June 11, 2026.

Since the rating, $HNGE is up 7.2% after 1 week, up 39.0% after 1 month and up 53.1% to date (from the $64.75 close on Jun 11, 2026).

HNGE Hinge Health, Inc.

$99.16 +117.65% year to date

Daily close · Oct 16, 2026

Key Points

RBC Capital reiterates a buy rating for Hinge Health, Inc. (HNGE) with a target price of $75, while the stock trades at $68.35.
RBC Capital's $75 price target implies 9.73% upside from Hinge Health, Inc.'s ($HNGE) current $68.35 share price.
The healthcare company has a market cap of about $8.47 billion and reported revenue of $720 million, reflecting a 53% year-over-year growth.
Analysts have a consensus price target of $112.13, with 16 opinions, indicating continued optimism for the stock's performance.

Get $HNGE trade alerts by text

We text you when insiders, Congress or big funds trade $HNGE. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Hinge Health, Inc. alert may contain errors. Disclosures

RBC Capital's Rating Reiterated

On June 11, 2026, RBC Capital reiterated its buy rating on Hinge Health, Inc. (HNGE) and raised its price target from $75 to $75. The stock closed at $68.35 on the NYSE, and RBC's latest assessment highlights confidence in the company's performance and potential growth.

Analysts Set New Price Targets

Keybanc, Barclays, Needham, Baird, Stifel, and Truist Securities have all maintained their ratings on Hinge Health, with their targets ranging from $90 to $140. On October 16, Keybanc maintained an Overweight rating with a target of $140, while Barclays raised its target to $110 on October 12. The average target across 16 analysts stands at $112.13, reflecting strong expectations for the company's future.

Business Overview

Hinge Health, Inc. focuses on using technology to improve healthcare delivery, particularly for musculoskeletal issues. It serves self-insured employers with AI-driven solutions for pain management and rehabilitation, which positions it well in the growing health tech sector.

What to Watch at Hinge Health, Inc.

Investors should pay attention to Hinge Health's next earnings report scheduled for November 2, 2026. This will provide further insights into its financial health and operational success following RBC Capital's optimistic outlook. The firm's 13F filings will also reveal any changes in institutional investment in the company.

12-month forecast